Formosa Pharmaceuticals, Inc. (TW: 6838), today announced the submission of a Clinical Trial Application (CTA) to European regulatory authorities to
Read More
Returning on 18- 20 March 2019 after a successful 2018 debut, Phar-East will once again bring together experts from Asian pharma & biotechs, big pharma, regulators, payers, technology innovators and more to share their expertise and chart Asia’s path forward.
Read More
In the lead up to the Bio Connections Australia 13-14 November, Melbourne conference, we spoke with US-based pharmaceutical firm, Cerebral Therapeutics, who have recently undertaken a proof of concept clinical study in Australia, using a proprietary formulation to treat refractory epilepsy.
Read More
Organised by IBC Asia, the annual Biopharma Development & Production (BDP) Week took place on 16 – 17 May 2018 at Hilton Shanghai Hongqiao Hotel.
Read More
Taipei, Taiwan-based Lumosa Therapeutics Co., Ltd., a company focused on developing treatments for neurological and inflammatory disease, announced recently that it had engaged Cincinnati-headquartered Camargo Pharmaceutical Services for regulatory consulting and strategic development services for LT1001 (Naldebain®, dinalbuphine sebacate IM injection) in the US.
Read More
Singapore-headquartered ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted treatments for Asia prevalent cancer types, recently announced the signing of a research collaboration agreement with Academia Sinica’s Genomic Research Centre, one of Taiwan’s eminent research institutions.
Read More